Skip to Main Content

STAT’s national biotech columnist, Adam Feuerstein, is holding a subscriber-only chat on Thursday to discuss the clinical trials, FDA approval decisions, and other events that will impact sentiment and move stocks through the end of the year.

To seed the discussion, read Adam’s scorecard of important biotech events for the fourth quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.